Registry update — unassessed
Evaluation of the Impact of Physical Exercise on Metabolic Dysfunction-associated Steatotic Liver Disease in the Elderly
Trial registry update: RECRUITING. No results reported in the supplied registry record.
RCTMinor significance
What this changes
The finding has not established an approved change to our evidence assessment.
Source date: Oct 26, 2026 · Discovered: Oct 26, 2026 · Assessed: — · Research update
What it does not prove
- This document reports only the trial protocol, not actual findings or efficacy of exercise for liver disease
- No participant enrollment numbers, completion rates, or baseline characteristics are provided
- The study design creates an imbalance: only one group (middle-aged, low-risk MASLD) has a control arm without exercise, limiting causal inference for other comparisons
Extracted from supplied source material; model confidence is not a measured probability of correctness.
Study details
- Design
- Rct
- Sample size
- —
- Duration
- 3 months
- Population
- Adults with metabolic dysfunction-associated steatotic liver disease (MASLD) or at-risk metabolic dysfunction-associated steatohepatitis (MASH): middle-aged adults (40-60 years old) and older adults (70 years and older) of any sex
- Primary outcome
- Reduction in liver fat, inflammation and fibrosis
- Effect size
- —
- Significance
- Not reported
- Journal
- Consorcio Centro de Investigación Biomédica en Red (CIBER)
- Published
- Oct 26, 2026
Sources
Primary source
Recorded source passages
Abstract or registry material supplied for assessment; source version 1. This is not a claim of full-text review.
The goal of this clinical trial is to learn how physical exercise affects liver health in adults with metabolic dysfunction-associated steatotic liver disease (MASLD) or at-risk metabolic dysfunction-associated steatohepatitis (MASH); comparing responses between middle-aged adults (40-60 years old) and older adults (70 years and older) of any sex, as well as between participants with low-risk MASLD and high-risk MASH.
The main question it aims to answer is: Could an exercise program reduce liver fat, inflammation and fibrosis, regardless of age and disease severity?
Researchers will compare 4 different groups: A) older adults with at risk MASH who will exercise B) middle-aged people with at risk MASH who will exercise C) middle-aged people with low-risk MASLD who will exercise D) middle-aged people with low-risk MASLD who will not exercise, receiving usual care.
Participants in the exercise groups will take part in a supervised 12-week exercise program that includes both strength and aerobic training, completed twice a week.
All participants, including those receiving usual care, will have health asssessments before and after the 12-week period to measure changes in liver health.
Assessment history
Discussion (0)
One thread per scientific event, no matter how many outlets covered it.
Sign in to join the discussion.
No comments yet
Be the first to weigh in on this evidence.